A single-site, three-arm, pharmacokinetic Phase I trial of JHL1149 in healthy volunteers
Phase of Trial: Phase I
Latest Information Update: 22 Dec 2017
At a glance
- Drugs Bevacizumab (Primary)
- Indications Colorectal cancer; Lung cancer; Ovarian cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors JHL Biotech
- 22 Dec 2017 New trial record
- 20 Dec 2017 According to a JHL Biotech media release, the company is planning this study in healthy volunteers in Sofia, Bulgaria beginning March 2018.
- 15 Dec 2017 According to a JHL Biotech media release, the company has submitted a Clinical Trial Application (CTA) to European authorities to initiate this trial.